FRES
Fresh2 Group LtdNASDAQHEALTHCAREDIAGNOSTICS & RESEARCH
Key Statistics
Market Cap
$2.97M
P/E Ratio
—
EPS
$-72.68
Beta
1.28
52W High
$0.00
52W Low
$0.00
50-Day MA
$1.49
200-Day MA
$3.06
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Fresh2 Group Ltd
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | $16.98M |
| Gross Profit (TTM) | 0 |
| EBITDA | $-115.58M |
| Operating Margin | -699.00% |
| Return on Equity | -216.20% |
| Return on Assets | -62.00% |
| Revenue/Share (TTM) | $38.32 |
| Book Value | $103.01 |
| Price-to-Book | 0.17 |
| Price-to-Sales (TTM) | 0.12 |
| EV/Revenue | 0.881 |
| EV/EBITDA | -0.15 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -69.90% |
| Shares Outstanding | $2.45M |
| Float | $137.61M |
| % Insiders | 0.00% |
| % Institutions | 0.05% |
Historical Volatility
HV 10-Day
0.00%
HV 20-Day
0.00%
HV 30-Day
0.00%
HV 60-Day
0.00%
HV Rank
35.3%
Volatility is currently contracting
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on FRES and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026